98%
921
2 minutes
20
In this study, we designed and developed systems composed of poly(ethylene-oxide)--poly(ε-caprolactone) block copolymers of different molecular weights and compositions, non-ionic surfactant, and cyclodextrins. The innovation of this study lies in the combination of these diverse biomaterials to create biomimetic and bioinspired drug delivery supramolecular structures. The systems were formed by the thin-film hydration method. Extensive physicochemical and morphological characterization was conducted using differential scanning calorimetry, light scattering techniques, microcalorimetry analysis, high-resolution ultrasound spectroscopy, surface tension measurements, fluorescence spectroscopy, cryogenic transmission electron microscopy images, and cytotoxicity evaluation. These innovative hybrid nanoparticles were found to be attractive candidates as drug delivery systems with unique properties by encompassing the physicochemical and thermotropic properties of both classes of materials. Subsequently, Ropinirole hydrochloride was used as a model drug for the purpose of this study. These systems showed a high RH content (%), and diffusion experiments revealed that more than 90% of the loading dose was released under pH and temperature conditions that simulate the conditions of the nasal cavity. Promising drug release performance was observed with all tested formulations, worth further investigation to explore both permeation through the nasal mucosa and performance in an experimental animal model.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1039/d4tb00489b | DOI Listing |
Front Microbiol
August 2025
Metabolic Hepatobiliary and Pancreatic Diseases Key Laboratory of Luzhou City, Academician (Expert) Workstation of Sichuan Province, Department of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Subclinical mastitis (SCM) is a widespread but frequently undetected condition in dairy cows, leading to reduced milk quality and compromised animal health. This study utilizes an integrated multi-omics strategy encompassing metabolomics and microbiome analyses to investigate the systemic effects of SCM across four biological matrices: blood, milk, feces, and rumen fluid. Our findings reveal significant alterations in hematological and biochemical parameters, with key biomarkers such as digalacturonic acid and N-ε-methyl-L-lysine indicating systemic metabolic and immune dysregulation.
View Article and Find Full Text PDFJ Neurochem
August 2025
Drug Discovery Research Department, K Pharma, Inc., Fujisawa-shi, Kanagawa, Japan.
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by motor neuron (MN) degeneration. Ropinirole hydrochloride (ROPI), a dopamine receptor D2 (DRD2) agonist, was identified through phenotypic screening of MNs derived from patient-derived induced pluripotent stem cells (iPSCs) as a disease model and has emerged as a promising candidate drug for ALS treatment. The ROPALS trial, a phase I/IIa trial in patients with ALS, suggested the safety and efficacy of ROPI, albeit in a small sample size.
View Article and Find Full Text PDFMed Lett Drugs Ther
July 2025
J Pharm Bioallied Sci
May 2025
Department of Pharmaceutics, Vinayaka Mission's College of Pharmacy, Salem, Tamil Nadu, India.
Background: Restless Leg Syndrome (RLS) has a major impact on the quality of life and requires innovative approaches to improve symptom management. This study focuses on the design and development of Ropinirole-loaded nanoparticles for targeted intranasal delivery to enhance therapeutic outcomes in RLS patients.
Materials And Methods: Ropinirole, a dopamine agonist, was incorporated into chitosan nanoparticles with the help of the Box-Behnken design (BBD) to optimize key parameters such as particle size, polydispersity index (PDI), entrapment efficiency of the drug, and drug release kinetics.
NPJ Parkinsons Dis
May 2025
Basal Ganglia Pathophysiology Unit, Department of Experimental Medical Science, Lund University, Lund, Sweden.
Dopamine replacement therapy for Parkinson's disease can induce impulsive-compulsive behaviours (ICBs). Here we compare the D2/3 agonist ropinirole and L-DOPA, given alone or combined, with regard to their potential to induce ICBs in rats sustaining bilateral striatal injections of 6-hydroxydopamine. Daily treatment with ropinirole (2.
View Article and Find Full Text PDF